FY26 Full Year Results Announcement

• Strong revenue growth with improved Operating EBITDA margin of 20.9%
• Increase in Operating NPAT by 50.1% to $47.4m
• Fully franked final dividend of 6.0 cents per share, up 50%

Integral Diagnostics Limited (ASX: IDX) announced its financial results for the year ended 30 June 2026, showing strong performance across various metrics. Key highlights include a 25.6% increase in revenue to $788.7 million, a 30.3% rise in Operating EBITDA to $164.8 million, and an Operating EBITDA margin of 20.9%, up 80 basis points from the previous year. Operating NPAT increased by 50.1% to $47.4 million, and Operating diluted EPS grew by 23.6% to 12.6 cents. The company also reported a strong cash flow conversion of 82.0% and a fully franked final dividend of 6.0 cents per share, totaling 9.3 cents per share for FY26, reflecting a 50% increase from the prior year. The balance sheet remained robust with a reduced leverage ratio of 2.3x.

Revenue of $788.7m, Operating EBITDA of $164.8m, Operating NPAT of $47.4m, Operating diluted EPS of 12.6 cents

IDX is well positioned to benefit from favorable industry fundamentals, including increasing demand for diagnostic imaging services and growth in higher-value modalities. The company aims for sustainable revenue growth, EBITDA margin improvement, increased productivity, and improved patient access.